drugset / Trial / NCT00139919
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
Phase 2
Completed
Solvay Pharmaceuticals
H. Lundbeck A/S · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an optional open-label 26-week extension study.
Timeline
- Start
- 2006-01
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifeprunox | Small molecule | 40 mg | — |